Literature DB >> 27890935

NUP98-fusion transcripts characterize different biological entities within acute myeloid leukemia: a report from the AIEOP-AML group.

V Bisio1, M Zampini2, C Tregnago1, E Manara2, V Salsi3, A Di Meglio2, R Masetti4, M Togni4, D Di Giacomo5, S Minuzzo6, A Leszl7, V Zappavigna8, R Rondelli4, C Mecucci5, A Pession4, F Locatelli9, G Basso1, M Pigazzi1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2016        PMID： 27890935     DOI： 10.1038/leu.2016.361

Source DB:  PubMed          Journal:  Leukemia        ISSN： 0887-6924            Impact factor:   11.528


× No keyword cloud information.
  15 in total

1.  NUP98 fusion oncoproteins promote aneuploidy by attenuating the mitotic spindle checkpoint.

Authors:  Valentina Salsi; Silvia Ferrari; Paolo Gorello; Sebastian Fantini; Francesca Chiavolelli; Cristina Mecucci; Vincenzo Zappavigna
Journal:  Cancer Res       Date:  2013-12-26       Impact factor: 12.701

2.  NUP98/NSD1 characterizes a novel poor prognostic group in acute myeloid leukemia with a distinct HOX gene expression pattern.

Authors:  Iris H I M Hollink; Marry M van den Heuvel-Eibrink; Susan T C J M Arentsen-Peters; Marta Pratcorona; Saman Abbas; Jenny E Kuipers; Janneke F van Galen; H Berna Beverloo; Edwin Sonneveld; Gert-Jan J L Kaspers; Jan Trka; Andre Baruchel; Martin Zimmermann; Ursula Creutzig; Dirk Reinhardt; Rob Pieters; Peter J M Valk; C Michel Zwaan
Journal:  Blood       Date:  2011-08-02       Impact factor: 22.113

Review 3.  Biology, risk stratification, and therapy of pediatric acute leukemias: an update.

Authors:  Ching-Hon Pui; William L Carroll; Soheil Meshinchi; Robert J Arceci
Journal:  J Clin Oncol       Date:  2011-01-10       Impact factor: 44.544

4.  Characterization of children with FLT3-ITD acute myeloid leukemia: a report from the AIEOP AML-2002 study group.

Authors:  E Manara; G Basso; M Zampini; B Buldini; C Tregnago; R Rondelli; R Masetti; V Bisio; M Frison; K Polato; G Cazzaniga; G Menna; F Fagioli; P Merli; A Biondi; A Pession; F Locatelli; M Pigazzi
Journal:  Leukemia       Date:  2016-06-28       Impact factor: 11.528

5.  NUP98 is rearranged in 3.8% of pediatric AML forming a clinical and molecular homogenous group with a poor prognosis.

Authors:  S Struski; S Lagarde; P Bories; C Puiseux; N Prade; W Cuccuini; M-P Pages; A Bidet; C Gervais; M Lafage-Pochitaloff; C Roche-Lestienne; C Barin; D Penther; N Nadal; I Radford-Weiss; M-A Collonge-Rame; B Gaillard; F Mugneret; C Lefebvre; E Bart-Delabesse; A Petit; G Leverger; C Broccardo; I Luquet; M Pasquet; E Delabesse
Journal:  Leukemia       Date:  2016-10-03       Impact factor: 11.528

6.  NUP98/JARID1A is a novel recurrent abnormality in pediatric acute megakaryoblastic leukemia with a distinct HOX gene expression pattern.

Authors:  J D E de Rooij; I H I M Hollink; S T C J M Arentsen-Peters; J F van Galen; H Berna Beverloo; A Baruchel; J Trka; D Reinhardt; E Sonneveld; M Zimmermann; T A Alonzo; R Pieters; S Meshinchi; M M van den Heuvel-Eibrink; C Michel Zwaan
Journal:  Leukemia       Date:  2013-03-27       Impact factor: 11.528

7.  Results of the AIEOP AML 2002/01 multicenter prospective trial for the treatment of children with acute myeloid leukemia.

Authors:  Andrea Pession; Riccardo Masetti; Carmelo Rizzari; Maria Caterina Putti; Fiorina Casale; Franca Fagioli; Matteo Luciani; Luca Lo Nigro; Giuseppe Menna; Concetta Micalizzi; Nicola Santoro; Anna Maria Testi; Marco Zecca; Andrea Biondi; Martina Pigazzi; Sergio Rutella; Roberto Rondelli; Giuseppe Basso; Franco Locatelli
Journal:  Blood       Date:  2013-05-14       Impact factor: 22.113

8.  CBFA2T3-GLIS2 fusion transcript is a novel common feature in pediatric, cytogenetically normal AML, not restricted to FAB M7 subtype.

Authors:  Riccardo Masetti; Martina Pigazzi; Marco Togni; Annalisa Astolfi; Valentina Indio; Elena Manara; Rita Casadio; Andrea Pession; Giuseppe Basso; Franco Locatelli
Journal:  Blood       Date:  2013-02-13       Impact factor: 22.113

Review 9.  Collaborative Efforts Driving Progress in Pediatric Acute Myeloid Leukemia.

Authors:  C Michel Zwaan; Edward A Kolb; Dirk Reinhardt; Jonas Abrahamsson; Souichi Adachi; Richard Aplenc; Eveline S J M De Bont; Barbara De Moerloose; Michael Dworzak; Brenda E S Gibson; Henrik Hasle; Guy Leverger; Franco Locatelli; Christine Ragu; Raul C Ribeiro; Carmelo Rizzari; Jeffrey E Rubnitz; Owen P Smith; Lillian Sung; Daisuke Tomizawa; Marry M van den Heuvel-Eibrink; Ursula Creutzig; Gertjan J L Kaspers
Journal:  J Clin Oncol       Date:  2015-08-24       Impact factor: 44.544

10.  Small molecule inhibition of cAMP response element binding protein in human acute myeloid leukemia cells.

Authors:  B Mitton; H-D Chae; K Hsu; R Dutta; G Aldana-Masangkay; R Ferrari; K Davis; B C Tiu; A Kaul; N Lacayo; G Dahl; F Xie; B X Li; M R Breese; E M Landaw; G Nolan; M Pellegrini; S Romanov; X Xiao; K M Sakamoto
Journal:  Leukemia       Date:  2016-05-23       Impact factor: 11.528
View more
  17 in total

Review 1.  Using genomics to define pediatric blood cancers and inform practice.

Authors:  Rachel E Rau; Mignon L Loh
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2018-11-30

2.  Dasatinib and navitoclax act synergistically to target NUP98-NSD1+/FLT3-ITD+ acute myeloid leukemia.

Authors:  Jarno L Kivioja; Angeliki Thanasopoulou; Ashwini Kumar; Mika Kontro; Bhagwan Yadav; Muntasir M Majumder; Komal K Javarappa; Samuli Eldfors; Juerg Schwaller; Kimmo Porkka; Caroline A Heckman
Journal:  Leukemia       Date:  2018-12-19       Impact factor: 11.528

3.  Somatic mutations in murine models of leukemia and lymphoma: Disease specificity and clinical relevance.

Authors:  Liat Goldberg; Sheryl M Gough; Fan Lee; Christine Dang; Robert L Walker; Yuelin J Zhu; Sven Bilke; Marbin Pineda; Masahiro Onozawa; Yang Jo Chung; Paul S Meltzer; Peter D Aplan
Journal:  Genes Chromosomes Cancer       Date:  2017-03-31       Impact factor: 5.006

Review 4.  The genomics of acute myeloid leukemia in children.

Authors:  Shannon E Conneely; Rachel E Rau
Journal:  Cancer Metastasis Rev       Date:  2020-03       Impact factor: 9.264

5.  Thioridazine requires calcium influx to induce MLL-AF6-rearranged AML cell death.

Authors:  Claudia Tregnago; Ambra Da Ros; Elena Porcù; Maddalena Benetton; Manuela Simonato; Luca Simula; Giulia Borella; Katia Polato; Sonia Minuzzo; Giulia Borile; Paola Cogo; Silvia Campello; Alessandro Massi; Romeo Romagnoli; Barbara Buldini; Franco Locatelli; Martina Pigazzi
Journal:  Blood Adv       Date:  2020-09-22

Review 6.  Mechanistic insights and potential therapeutic approaches for NUP98-rearranged hematologic malignancies.

Authors:  Nicole L Michmerhuizen; Jeffery M Klco; Charles G Mullighan
Journal:  Blood       Date:  2020-11-12       Impact factor: 22.113

Review 7.  Prognostic mutation constellations in acute myeloid leukaemia and myelodysplastic syndrome.

Authors:  Ilaria Iacobucci; Charles G Mullighan
Journal:  Curr Opin Hematol       Date:  2021-03-01       Impact factor: 3.284

8.  Acute erythroid leukemia is enriched in NUP98 fusions: a report from the Children's Oncology Group.

Authors:  Karen M Chisholm; Amy E Heerema-McKenney; John K Choi; Jenny Smith; Rhonda E Ries; Betsy A Hirsch; Susana C Raimondi; Todd A Alonzo; Yi-Cheng Wang; Richard Aplenc; Lillian Sung; Alan S Gamis; Soheil Meshinchi; Samir B Kahwash
Journal:  Blood Adv       Date:  2020-12-08

9.  NUP-98 Rearrangements Led to the Identification of Candidate Biomarkers for Primary Induction Failure in Pediatric Acute Myeloid Leukemia.

Authors:  Vincenza Barresi; Virginia Di Bella; Nellina Andriano; Anna Provvidenza Privitera; Paola Bonaccorso; Manuela La Rosa; Valeria Iachelli; Giorgia Spampinato; Giulio Pulvirenti; Chiara Scuderi; Daniele F Condorelli; Luca Lo Nigro
Journal:  Int J Mol Sci       Date:  2021-04-27       Impact factor: 5.923

10.  First case report of a NUP98-PMX1 rearrangement in de novo acute myeloid leukemia and literature review.

Authors:  Weijia Fu; Aijie Huang; Hui Cheng; Yanrong Luo; Lei Gao; Gusheng Tang; Jianmin Yang; Jianmin Wang; Xiong Ni
Journal:  BMC Med Genomics       Date:  2021-05-17       Impact factor: 3.063
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.